New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
10:02 EDTVTR, SLXP, MYL, JEC, GT, ENDP, CBI, ARCP, VRX, PRGO, MW, HST, ESS, DRH, BR, ACT, TEVA, PKY, MNK, HSP, EQR, CTB, BDNOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Actavis (ACT) initiated with a Buy at Deutsche Bank... American Realty (ARCP) initiated with a Perform at Oppenheimer... Brandywine Realty (BDN) initiated with a Neutral at Mizuho... Broadridge (BR) initiated with an Outperform at Raymond James... Chicago Bridge & Iron (CBI) initiated with a Market Perform at Wells Fargo... Cooper Tire (CTB) initiated with a Neutral at JPMorgan... DiamondRock (DRH) initiated with a Neutral at ISI Group... Endo (ENDP) initiated with a Buy at Deutsche Bank... Equity Residential (EQR) initiated with a Neutral at Mizuho... Essex Property Trust (ESS) initiated with a Buy at Mizuho... Fluor (FLR) initiated with an Outperform at Wells Fargo... Goodyear Tire (GT) initiated with an Overweight at JPMorgan... Hospira (HSP) initiated with a Hold at Deutsche Bank... Host Hotels (HST) initiated with a Neutral at ISI Group... Jacobs Engineering (JEC) initiated with an Outperform at Wells Fargo... Jazz Pharmaceutical initiated with a Buy at Buckingham... Mallinckrodt (MNK) initiated with a Buy at Deutsche Bank... Men's Wearhouse (MW) reinstated with a Buy at Goldman... Mylan (MYL) initiated with a Buy at Deutsche Bank... Parkway Properties (PKY) initiated with a Neutral at Mizuho... Perrigo (PRGO) initiated with a Buy at Deutsche Bank... Salix (SLXP) initiated with a Hold at Deutsche Bank... Teva (TEVA) initiated with a Buy at Deutsche Bank... Valeant (VRX) initiated with a Hold at Deutsche Bank... Ventas (VTR) initiated with a Buy at Mizuho.
News For ACT;ARCP;BDN;BR;CBI;CTB;DRH;ENDP;EQR;ESS;GT;HSP;HST;JEC;MNK;MW;MYL;PKY;PRGO;SLXP;TEVA;VRX;VTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>
February 17, 2015
17:16 EDTACTActavis confirms temporary injunction related to generic Pulmicort RESPULES
Subscribe for More Information
17:13 EDTVRXPoint72 gives quarterly update on stakes
Subscribe for More Information
17:02 EDTENDP, ACTSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
15:32 EDTACTNotable companies reporting before tomorrow's open
Subscribe for More Information
13:52 EDTACTEarnings Preview: Actavis near 52-week high ahead of Q4 earnings report
Subscribe for More Information
13:18 EDTACTOmega Advisors gives quarterly update on stakes
Subscribe for More Information
10:51 EDTSLXPOptions with decreasing implied volatility
Subscribe for More Information
10:12 EDTGTGoodyear Tire moves higher after earnings, levels to watch
At the last price of $26.95, the stock is up over 3.3% on the day following its earning report before market open. Resistance is at the high of the day at $27.22 and then at $27.51, the bottom of a bearish gap down in price from January. Support is at the 50-day moving average, last at $26.57.
08:47 EDTTEVABioTime provides update on Cell Cure's product development, partnering
BioTime (BTX) and its subsidiary Cell Cure Neurosciences provided an update on Cell Cure’s product development and partnering activities. On February 16, Cell Cure opened the clinical trial of OpRegen titled “Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients with Advanced Dry-Form Age-Related Macular Degeneration with Geographic Atrophy” at Hadassah University Medical Center in Jerusalem, Israel. Patient enrollment is expected to begin shortly. OpRegen consists of animal product-free retinal pigment epithelial cells with high purity and potency. On October 31, 2014, the FDA cleared Cell Cure's Investigational New Drug application to initiate the clinical trial of OpRegen in patients with the severe form of age-related macular degeneration with geographic atrophy.The Phase I/IIa clinical trial, will evaluate three different dose regimens of OpRegen. Following transplantation, the patients will be followed for 12 months at specified intervals, to evaluate the safety and tolerability of the product. Following the initial 12 month period, patients will continue to be monitored at longer intervals for an additional period of time. A secondary objective of the clinical trial will be to examine the ability of transplanted OpRegen to engraft, survive, and moderate disease progression in the patients. In addition to thorough characterization of visual function, a battery of ophthalmic imaging modalities will be used to quantify structural changes and rate of GA expansion. Cell Cure also announced that the option granted to Teva (TEVA) under a Research and Exclusive Option Agreement of October 7, 2010 to license-in rights to its OpRegen product has expired without having been exercised by Teva. Cell Cure will therefore be continuing the clinical development of OpRegen on its own and pursuing discussions with other potential strategic partners, including those that have already indicated interest in participating in development and commercialization of the product. Cell Cure also announced that US patent No. 8,956,866 relating to a proprietary method of manufacturing RPE cells is expected to issue on February 17. This patent combined with other patents and patent applications in the BioTime family of companies provides significant patent protection for this novel therapeutic modality for AMD.
08:39 EDTTEVATeva deal small but important, says BMO Capital
Subscribe for More Information
08:35 EDTTEVATeva announces launch of generic Lovenox and Zyvox in U.S.
Subscribe for More Information
08:18 EDTPRGOPerrigo weakness creates buying opportunity, says Argus
Subscribe for More Information
08:18 EDTGTGoodyear Tire backs 2015-2016 operating income growth of 10%-15%
Backs 2015-2016 annual positive free cash flow from operations and an adjusted debit to EBITDAP ratio of 2.0x to 2.1x.
08:17 EDTGTGoodyear Tire reports Q4 Tire unit volumes totaled 39.5M
Original equipment unit volume was down 1 percent, primarily due to continued industry weakness in Latin America. Replacement tire shipments were down 4 percent, due to lower sales of winter tires in Europe resulting from one of the warmest winters on record.
08:17 EDTGTGoodyear Tire reports Q4 EPS excl items 59c, consensus 58c
Subscribe for More Information
07:49 EDTJECJacobs selected as executive architect for new Wynn Resorts development
Jacobs Engineering Group has been selected as Executive Architect and Engineer for the new Wynn Resorts development in Everett, Mass. Company officials did not disclose the contract value. Under the terms of the contract, Jacobs is leading a local team of architects and engineers assembled to take on the technically complex assignment of converting a former industrial site on the Everett waterfront to a $1.6B luxury resort that is being designed to echo grand hotels of the past. Construction is expected to begin by late summer of 2015 with a grand opening targeted for first quarter 2018.
07:24 EDTPRGOPerrigo management to meet with UBS
Subscribe for More Information
07:04 EDTTEVATeva, Eagle enter license agreement for EP-3102
Teva Pharmaceutical Industries (TEVA) and Eagle Pharmaceuticals (EGRX) announce that the companies have entered into an exclusive license agreement for EP-3102, Eagle’s bendamustine hydrochloride rapid infusion product for the treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. Teva will be responsible for all U.S. commercial activities for the product including promotion and distribution. Eagle has responsibility for obtaining all regulatory approvals, conducting post-approval clinical studies, if required, and initially supplying drug product to Teva. As part of the agreement, Teva will waive its orphan drug exclusivities for NHL and CLL with respect to EP-3102, which should allow the product to come to market more quickly. Under the terms of the exclusive license agreement, Eagle will receive an upfront cash payment of $30M and is eligible to receive up to $90M in additional milestone payments. In addition, Eagle will receive double-digit royalties on net sales of the product, assuming FDA approval. The companies will also settle the pending patent infringement action between them.
05:00 EDTGTGoodyear Tire volatility elevated into Q4 and outlook
Goodyear Tire February call option implied volatility is at 90, March is at 43, April is at 33; compared to its 26-week average of 36 according to Track Data. Elevated volatility suggests traders taking positions for large price movement into the expected release of Q4 results today.
04:47 EDTHSPPfenex price target raised to $16 from $12 at Mizuho
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use